SUVEN

March 21 (Reuters) - Suven Life Sciences Ltd SUVP.NS:

• SUVEN LIFE SCIENCES LTD - GOT TAX ORDER FOR DEMAND 17.6 MILLION RUPEES

Source text: ID:nBSE98wdX9

Further company coverage: SUVP.NS

(([email protected];))

** Suven Pharmaceuticals SUVH.NS jumps 7.3% to 1,125.2 rupees; set for biggest one-day pct gain since June 27, 2024

** Q3 consol net profit surges 77% y/y, boosted by strong demand in its contract manufacturing business; rev up 40%

** Stock set to snap four straight days of declines

** More than 2.6 mln shares traded, over 12x the 30-day avg

** SUVH gained 57% in 2024

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

** Suven Life Sciences SUVP.NS rises as much as 14.3% to 144.4 rupees, highest since Dec. 20, 2024

** Pharma co says the first subjects of SUVN-I6107's Phase 1 clinical trial have been dosed; SUVN-I6107 is used to treat cognitive disorders

** Adds study's primary objective is to assess drug's safety and tolerability

** Stock gains 8% so far this week

** More than 1 mln shares traded, 3.3x the 30-day avg, in stock's busiest day since Dec. 10, 2024

** SUVP gained 58.4% in 2024 - second consecutive year of gains

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

Oct 3 (Reuters) - Suven Life Sciences Ltd SUVP.NS:

• TO PRESENT POSITIVE RESULTS FROM PHASE-2A PROOF-OF-CONCEPT STUDY OF ROPANICANT

• TO ADVANCE ROPANICANT INTO DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE-2B STUDY

Source text for Eikon: ID:nBSE6Btb99

Further company coverage: SUVP.NS

(([email protected];;))

Sept 18 (Reuters) - Suven Life Sciences Ltd SUVP.NS:

• SUVEN LIFE SCIENCES - ANNOUNCES POSITIVE RESULTS FROM PHASE-2A STUDY OF SUVN-911

• SUVEN LIFE SCIENCES - SUVN-911 STUDY FOR TREATMENT OF MODERATE TO SEVERE MAJOR DEPRESSIVE DISORDER

Further company coverage: SUVP.NS

(([email protected];))

** Shares of biopharmaceutical company Suven Life Sciences SUVP.NS rise as much as 5.4% to hit record high at 161 rupees

** SUVN says U.S. FDA has accepted its investigational new drug (IND) application

** Adds, FDA has granted “study may proceed letter” to begin human study of drug for treating dementia

** Trading vol 1.7x 30-day daily avg

** Stock up 6.7% so far in August, on track for its third straight monthly gain

** Stock up 90.3% YTD

(Reporting by Ashish Chandra in Bengaluru)

(([email protected] (+91 7982114624))

** Shares of Suven Pharmaceuticals Ltd SUVH.NS up 4.9% at 700.50 rupees

** Contract drug manufacturer acquires smaller peer Sapala Organics for 2.3 billion rupees ($27.5 million) to bolster its contract and development manufacturing services (CDMO) business

** Earlier this year, SUVH merged with another CDMO firm, Cohance

** Sapala's "robust" margin profile and strong presence in Japan among key reasons for acquisition - SUVH presentation

** Over 305,000 shares traded, 1.6x 30-day avg volume

** Stock trims YTD losses to 4.3%, trails pharma stocks' .NIPHARM ~18% rise

($1 = 83.5300 Indian rupees)

(Reporting by Nandan Mandayam in Bengaluru)

(([email protected]; Mobile: +91 9591011727;))

** Shares of Suven Pharmaceuticals Ltd SUVH.NS fall as much as 4.8% to 602 rupees, their lowest since March 18

** Co reported a ~57% fall in its fourth-quarter consol net profit to 533.7 mln rupees ($6.4 mln), while rev fell 31.5% Y/Y

** "Revenue growth was impacted by shipment delays caused by client-specific inventory de-stocking," co said in a statement

** Stock on track to fall for the second straight day

** More than 581,000 shares traded as of 11:56 a.m. IST, 4.8x their 30-day moving avg

** SUVH last down 1.6%, adding to YTD losses of ~14.4%

($1 = 83.2875 Indian rupees)

(Reporting by Meenakshi Maidas in Bengaluru)

(([email protected];))

May 6 (Reuters) - Suven Life Sciences Ltd SUVP.NS:

• RE- APPOINTMENT OF VENKATESWARLU JASTI AS MD

Source text for Eikon: ID:nBSE5shl8X

Further company coverage: SUVP.NS

(([email protected];;))

** Shares of Suven Pharmaceuticals SUVH.NS up 12% in heavy volumes

** Stock eyes best day in more than 3 years

** Contract drug maker said it will merge with privately held Cohance Lifesciences in an all-stock deal to boost its contract and development manufacturing services (CDMO) business

** Trading volume tops 3 mln shares, more than 10x the 30-day moving avg

** Thursday's gains trim YTD losses to 2.5%; stock surged 46% in 2023

(Reporting by Kashish Tandon in Bengaluru)

(([email protected]))

HYDERABAD, Feb 29 (Reuters) - Indian contract drug manufacturer Suven Pharmaceuticals SUVH.NS said on Thursday it will merge with Cohance Lifesciences in an all-share deal, as it looks to further scale up its contract and development manufacturing services (CDMO) business.

The company, however, did not mention the deal value.

Under the deal, all shareholders of privately held Cohance will be issued 11 shares of Suven for every 295 shares of Cohance based on the swap ratio, Suven said on Thursday.

Private equity firm Advent International wholly owns Cohance and has a significant stake in Suven Pharma, which was demerged from its parent entity Suven Life Sciences SUVP.NS in 2020.

The combined entity, which Advent has been looking to merge since 2022, will be 66.7% owned by Advent's entities and the remaining 33.3% will be held by public shareholders, the company said.

The merged platform will comprise three distinct business units - contract drug manufacturing of pharmaceuticals, specialty chemicals and active pharmaceutical ingredients (API), which are key elements added to drugs to produce desired health effects.

"Cohance's addition, particularly its fast-growing ADC (antibody-drug conjugates used in treating cancer) platform, reinforces our position as a leading CDMO platform," Suven said.

The addition of Cohance's API business will scale up Suven's formulation business, according to the company.

India's contract drug manufacturers are seeing a boost in their business as global pharmaceutical companies are looking for services outside of China in an attempt to diversify their supply chain.

"Proposed merger expected to be double-digit EPS accretive (without synergies) from first year of it being effective," Suven said.

The transaction is expected to conclude over the next 12-15 months subject to shareholder regulatory approvals, the company said.

($1 = 82.8699 Indian rupees)

(Reporting by Rishika Sadam; Editing by Shweta Agarwal)

(([email protected];))

** Shares of Suven Pharmaceuticals SUVH.NS up 1.4% at 673.85 rupees

** Co says two facilities have completed U.S. FDA inspections and no Form 483 was issued; form is issued when violations are observed, per FDA website

** Stock on track to end four-day losing streak if trend holds

** Stock surges as much as 5.2% to its highest level in a month

** Since slumping on Feb. 6 after Q3 profit drop, stock has regained 9.4%

(Reporting by Varun Vyas in Bengaluru)

(([email protected]))

** Shares of Suven Pharmaceuticals SUVH.NS fall as much as 10.4% to 585.2 rupees, lowest level since Nov. 20

** The pharma co said on Monday its Q3 net profit more than halved to 523.6 mln rupees ($6.3 mln), rev from ops slipped ~39% Y/Y

** More than 665,000 shares change hands, 3.5x its 30-day avg

** Stock fell ~7% in January, snapping eight consecutive monthly gains

($1 = 83.0380 Indian rupees)

(Reporting by Ashna Teresa Britto in Bengaluru)

(([email protected] ; ( +91 8078332441))

** Suven Pharmaceuticals SUVH.NS shares 3.6% to 615 rupees, their highest since April 29, 2022

** Stock set for fourth straight day of gains, during which it has risen nearly 6%

** Stock has now gained 8.4% since the company posted results on Nov. 9

** Since then, the stock has also traded above its 50- ,100- and 200-day daily moving averages

** More than 380,000 shares traded by 1.28 p.m. IST, 1.4x the 30-day avg

** Stock up nearly 22% YTD, set for its best on-year gain since listing

(Reporting by Aleef Jahan in Bengaluru)

(([email protected]))

Oct 30 (Reuters) - Suven Life Sciences Ltd SUVP.NS:

• POSITIVE TOPLINE RESULTS FROM A PHASE-2 STUDY EVALUATING SAMELISANT EXCESSIVE DAYTIME SLEEPINESS

• PLANS TO APPROACH USFDA IN Q1 2024 FOR AN END-OF- PHASE-2 MEETING TO DISCUSS STUDY RESULTS

• PLANS TO SEEK USFDA'S GUIDANCE FOR PIVOTAL PHASE-3 STUDY

Source text for Eikon: ID:nBSExfcv0

Further company coverage: SUVP.NS

(([email protected];))